• 9245 Citations
1988 …2022
If you made any changes in Pure, your changes will be visible here soon.

Personal profile

Research Interests

Research Interests: Our laboratory concentrates its efforts into the investigation of the mechanistic connection between aging, cellular and/or mitochondrial metabolism, and carcinogenesis focusing on the Sirtuin gene family. To address this idea, over the past five years, we have constructed mice that have the three primary (Sirt1-3) sirtuins genetically deleted. The mice that lack Sirt1 (Wang et al., 2009, Cancer Cell), Sirt2 (Kim et al., 2011, Cancer Cell), and Sirt3 (Kim et al., 2010, Cancer Cell) each develop breast cancer, as well as other types of malignancies to varying degrees, and the levels of SIRT1-3 are also decreased in human cancer samples, as compared to normal tissues. In addition, the mechanism connecting the tumor permissive phenotype and the aberrant regulation of mitochondrial ROS, at least in part, in the Sirt3 knockout mouse has recently been published (Tao et al., 2010, Molecular Cell). Thus, based on these results it seems clear that the primary sirtuin deacetylase proteins are tumor suppressor in several breast cancers as well as to a lesser extent in several other human malignancies. These results seemed logical, since human sirtuins are the human homologs for the yeast and C. elegans longevity genes, and breast cancers have one of the strongest correlations to age. Thus, it is proposed that the primary sirtuin family knockout mice may present a novel group of models to establish, validate, and investigate the well established connection between aging, metabolism, and cancer. These murine models are also used to pursue the laboratories interest and the identification and validation of chemopreventative agents and we currently have a DOD and R01 grants to pursue this for luminal B breast malignancies. Finally, the laboratory has a series of murine in vivo and in vitro models to mechanistically connect Sirt2 and Sirt3 to cancers of the breast, pancreas, liver, and lung that are currently be used.

Certifications and Licenses

Radiation Oncology

Training Experience

1993Internship, Weiss Memorial Hospital
1994Residency, University of Michigan Hospital
1997Fellowship, Washington University Medical Center

Education/Academic qualification

MD, Loyola University/Stritch School of Medicine

… → 1992

PhD, University of Chicago

… → 1989

Research interests

  • Aging
  • Breast Cancer
  • Lung Injury
  • Radiation Oncology
  • Digestive Cancer (esophagus, stomach, colon, rectum)

Fingerprint Dive into the research topics where David R Gius is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 4 Similar Profiles
Neoplasms Medicine & Life Sciences
Ionizing Radiation Medicine & Life Sciences
Oxidation-Reduction Medicine & Life Sciences
Sirtuin 3 Medicine & Life Sciences
Acetylation Medicine & Life Sciences
Transcription Factor AP-1 Medicine & Life Sciences
Oxidative Stress Medicine & Life Sciences
Carcinogenesis Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Grants 2011 2022

Research Output 1988 2019

12 Citations (Scopus)

Efferocytosis Fuels Requirements of Fatty Acid Oxidation and the Electron Transport Chain to Polarize Macrophages for Tissue Repair

Zhang, S., Weinberg, S., DeBerge, M., Gainullina, A., Schipma, M. J., Kinchen, J. M., Ben-Sahra, I., Gius, D. R., Yvan-Charvet, L., Chandel, N., Schumacker, P. T. & Thorp, E. B., Feb 5 2019, In : Cell Metabolism. 29, 2, p. 443-456.e5

Research output: Contribution to journalArticle

Electron Transport
Fatty Acids

Homeostatic roles of STING in cell proliferation and chromosomal instability

Gius, D. & Zhu, Y., Jan 1 2019, In : Cancer Research. 79, 7, p. 1295-1296 2 p.

Research output: Contribution to journalArticle

Chromosomal Instability
Cell Proliferation
Cell Cycle
3 Citations (Scopus)

Lysine 68 acetylation directs MnSOD as a tetrameric detoxification complex versus a monomeric tumor promoter

Zhu, Y., Zou, X., Dean, A. E., Brien, J. O., Gao, Y., Tran, E. L., Park, S. H., Liu, G., Kieffer, M. B., Jiang, H., Stauffer, M. E., Hart, R., Quan, S., Satchell, K. J. F., Horikoshi, N., Bonini, M. & Gius, D., Dec 1 2019, In : Nature communications. 10, 1, 2399.

Research output: Contribution to journalArticle

Open Access
inorganic peroxides
3 Citations (Scopus)

Sirtuin 2–mediated deacetylation of cyclin-dependent kinase 9 promotes STAT1 signaling in type I interferon responses

Kosciuczuk, E. M., Mehrotra, S., Saleiro, D., Kroczynska, B., Majchrzak-Kita, B., Lisowski, P., Driehaus, C., Rogalska, A., Turner, A., Lienhoop, T., Gius, D., Fish, E. N., Vassilopoulos, A. & Platanias, L. C., Jan 1 2019, In : Journal of Biological Chemistry. 294, 3, p. 827-837 11 p.

Research output: Contribution to journalArticle

Cyclin-Dependent Kinase 9
Interferon Type I
Sirtuin 2
16 Citations (Scopus)

Emerging evidence for targeting mitochondrial metabolic dysfunction in cancer therapy

Zhu, Y., Dean, A. E., Horikoshi, N., Heer, C., Spitz, D. R. & Gius, D., Aug 31 2018, In : Journal of Clinical Investigation. 128, 9, p. 3682-3691 10 p.

Research output: Contribution to journalReview article

Electron Transport